U.S. markets open in 1 hour 24 minutes
  • S&P Futures

    +5.25 (+0.12%)
  • Dow Futures

    +83.00 (+0.23%)
  • Nasdaq Futures

    -27.50 (-0.18%)
  • Russell 2000 Futures

    +9.30 (+0.41%)
  • Crude Oil

    +0.80 (+0.97%)
  • Gold

    +11.50 (+0.65%)
  • Silver

    +0.20 (+0.85%)

    +0.0003 (+0.02%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -0.55 (-3.55%)

    -0.0008 (-0.06%)

    -0.0950 (-0.08%)

    -1,653.35 (-2.54%)
  • CMC Crypto 200

    -29.50 (-1.92%)
  • FTSE 100

    +40.47 (+0.56%)
  • Nikkei 225

    +96.27 (+0.34%)

Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Baxter International Inc. BAX recently announced the global launch of the latest version of its next-generation platform, PrisMax 2. The PrisMax 2 system aims to help streamline the delivery of continuous renal replacement therapy (“CRRT”) and other organ support therapies while allowing hospitals the flexibility to meet the requirements of the intensive care unit (ICU).

With the latest launch, Baxter aims to fortify its ground in the global Acute Therapies business.

A Few Words on PrisMax 2

The PrisMax 2 system boasts latest solutions within Baxter’s TrueVue digital health portfolio, as well as the PrismaLung+ blood-gas exchanger, which provides extracorporeal (situated or occurring outside the body) carbon dioxide removal (ECCO2R) therapy to enable acute respiratory dysfunction management.

Further, the PrisMax 2 system provides access to TrueVue digital health solutions to enhance patient care as well as deliver value to hospitals.

The PrisMax 2 and TrueVue will soon be available in the United States and various countries throughout Europe. Further, PrismaLung+ is available in select markets in western Europe, but is not currently cleared or approved for use in the United States.

Significance of the Launch

The PrisMax 2 system uses Baxter’s technology of its market-leading Prismaflex and PrisMax systems, and has been developed on the basis of direct feedback from clinicians and customers worldwide. The system is designed to optimize treatment accuracy, efficacy and system performance.

Apart from offering TrueVue and PrismaLung+, new advancements include updates to the system to offer enhanced visibility of critical information and simplified step-by-step onscreen instructions.

The PrismaLung+ blood-gas exchanger, which can be used on the PrisMax 2 system to deliver ECCO2R therapy, enables treatment of patients who may also require renal replacement therapy or other organ support therapies. This is possible without increasing any complication of delivery, staff training or new capital expenditure requirements.

Per management, the PrisMax 2 system has been developed with the aim of expanding treatment possibilities by making CRRT and other extracorporeal organ support therapies more accessible.

Industry Prospects

Per a report by MarketsAndMarkets, the global CRRT market is projected to reach $1,532.3 million by 2022 from $1,092.5 million in 2017 at a CAGR of 7%. Factors like increasing prevalence of acute renal failure and high prevalence of diabetes are likely to drive the market.

Given the market potential, the latest launch is expected to significantly strengthen Baxter’s global business.

Notable Developments

Of late, Baxter has witnessed a few notable developments across its businesses.

The company, in April, reported solid worldwide sales during first-quarter 2021 with the Acute Therapies segment being the primary driver.

Baxter, in March, received the FDA’s clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine. Notably, the AK 98 machine is designed to be a portable and easy-to-use system for administering hemodialysis treatments.

The same month, the company entered into an agreement with Moderna, Inc. MRNA with respect to the COVID-19 vaccines. Per the agreement, Baxter BioPharma Solutions would provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of Moderna’s vaccine in 2021.

Price Performance

Shares of the company have lost 9.7% in the past year against the industry’s 14.8% growth and the S&P 500's 38.5% rise.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Zacks Rank & Key Picks

Currently, Baxter carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Illumina, Inc. ILMN and DaVita Inc. DVA, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Illumina’s long-term earnings growth rate is estimated at 7%.

DaVita’s long-term earnings growth rate is estimated at 14.4%.

Time to Invest in Legal Marijuana

If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.

After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%.

You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.

Today, Download Marijuana Moneymakers FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Illumina, Inc. (ILMN) : Free Stock Analysis Report

Baxter International Inc. (BAX) : Free Stock Analysis Report

DaVita Inc. (DVA) : Free Stock Analysis Report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research